COVID pill S-217622 shows rapid clearance of virus: Shionogi

The company has global aspirations for the antiviral pill, which is now being evaluated by Japanese regulators.

Published On 2022-04-25 04:30 GMT   |   Update On 2022-04-25 09:33 GMT
Advertisement

Tokyo: An experimental treatment from Shionogi & Co Ltd has shown rapid clearance of the virus that causes Covid-19, according to new data, the Japanese drug maker said on Sunday.

The pill, S-217622, "demonstrated rapid clearance of the infectious SARS-CoV-2 virus", Shionogi said in a statement, citing Phase-2b results from the Phase II/III clinical trial of the drug.
The company has global aspirations for the antiviral pill, which is now being evaluated by Japanese regulators.
Advertisement
The findings released on Sunday also showed "there was no significant difference in total score of 12 Covid-19 symptoms between treatment arms" although the drug showed improvement in a composite score of five "respiratory and feverish" symptoms, Shionogi said.
The drugmaker said in March it would launch a global Phase III trial worldwide for the drug with US government support, and Chief Executive Isao Teshirogi has said production could reach 10 million doses a year.
Shionogi's shares have been on a rollercoaster on speculation about success of the treatment. The stock climbed on Friday after a report the US government is in talks to acquire supplies of the drug.
On April 13 the stock sank by as much as 16% on reports the drug could pose risks to pregnancies, based on preclinical data.

Read also: Zydus Lifesciences publishes phase 3 trials of Desidustat in American Journal of Nephrology

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News